New hope for older AML patients: testing a gentler drug combo
NCT ID NCT07014462
Summary
This early-stage study is testing whether adding a common anti-inflammatory drug (dexamethasone) to a standard, lower-intensity leukemia treatment is safe and tolerable. It's for adults newly diagnosed with acute myeloid leukemia (AML) who cannot undergo aggressive chemotherapy. The main goal is to check for side effects while also seeing if this combination helps control the cancer and improves quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML - ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.